Literature DB >> 1548461

Different glycosylation in acetylcholinesterases from mammalian brain and erythrocytes.

J Liao1, H Heider, M C Sun, U Brodbeck.   

Abstract

Acetylcholinesterases (EC 3.1.1.7, AChE) have varying amounts of carbohydrates attached to the core protein. Sequence analysis of the known primary structures gives evidence for several asparagine-linked carbohydrates. From the differences in molecular mass determined on sodium dodecyl sulfate-polyacrylamide gel before and after deglycosylation with N-glycosidase F (EC 3.2.2.18), it is seen that dimeric AChE from red cell membranes is more heavily glycosylated than the tetrameric brain enzyme. Furthermore, dimeric and tetrameric forms of bovine AChE are more heavily glycosylated than the corresponding human enzymes. Monoclonal antibodies 2E6, 1H11, and 2G8 raised against detergent-soluble AChE from electric organs of Torpedo nacline timilei as well as Elec-39 raised against AChE from Electrophorus electricus cross-reacted with AChE from bovine and human brain but not with AChE from erythrocytes. Treatment of the enzyme with N-glycosidase F abolished binding of monoclonal antibodies, suggesting that the epitope, or part of it, consists of N-linked carbohydrates. Analysis of N-acetylglucosamine sugars revealed the presence of N-acetylglucosamine in all forms of cholinesterases investigated, giving evidence for N-linked glycosylation. On the other hand, N-acetylgalactosamine was not found in AChE from human and bovine brain or in butyrylcholinesterase (EC 3.1.1.8) from human serum, indicating that these forms of cholinesterase did not contain O-linked carbohydrates. Despite the notion that within one species, the different forms of AChE arise from one gene by different splicing, our present results show that dimeric erythrocyte and tetrameric brain AChE must undergo different postsynthetic modifications leading to differences in their glycosylation patterns.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548461     DOI: 10.1111/j.1471-4159.1992.tb11333.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis.

Authors:  B Velan; C Kronman; A Ordentlich; Y Flashner; M Leitner; S Cohen; A Shafferman
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

2.  The assembly of proline-rich membrane anchor (PRiMA)-linked acetylcholinesterase enzyme: glycosylation is required for enzymatic activity but not for oligomerization.

Authors:  Vicky P Chen; Roy C Y Choi; Wallace K B Chan; K Wing Leung; Ava J Y Guo; Gallant K L Chan; Wilson K W Luk; Karl W K Tsim
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  Identification of organ-specific glycosylation of a membrane protein in two tissues using lectins.

Authors:  M Benallal; B M Anner
Journal:  Experientia       Date:  1994-07-15

4.  The membrane form of acetylcholinesterase from rat brain contains a 20 kDa hydrophobic anchor.

Authors:  N Boschetti; J Liao; U Brodbeck
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

5.  Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Authors:  Agneta Nordberg; Taher Darreh-Shori; Elaine Peskind; Hilkka Soininen; Malahat Mousavi; Gina Eagle; Roger Lane
Journal:  Curr Alzheimer Res       Date:  2009-02       Impact factor: 3.498

6.  Molecular Assembly and Biosynthesis of Acetylcholinesterase in Brain and Muscle: the Roles of t-peptide, FHB Domain, and N-linked Glycosylation.

Authors:  Vicky P Chen; Wilson K W Luk; Wallace K B Chan; K Wing Leung; Ava J Y Guo; Gallant K L Chan; Sherry L Xu; Roy C Y Choi; Karl W K Tsim
Journal:  Front Mol Neurosci       Date:  2011-10-25       Impact factor: 5.639

7.  Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.

Authors:  Magdalena Markowicz-Piasecka; Joanna Sikora; Łukasz Mateusiak; Elżbieta Mikiciuk-Olasik; Kristiina M Huttunen
Journal:  Oxid Med Cell Longev       Date:  2017-07-09       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.